Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach